Murine mantle cell lymphoma model cell line
نویسندگان
چکیده
منابع مشابه
Front-line treatment of mantle cell lymphoma.
In this issue of the Journal, Gressin et al. 1 publish the results of two phase II trials on newly diagnosed mantle cell lymphoma (MCL). In the first trial (LM1996), the treatment was infusion based vincristine and doxorubicin, oral dexamethasone and chlorambucil (VADC). Elderly patients received eight series while younger patients received six followed by high-dose melphalan and total-body irr...
متن کاملMantle Cell Lymphoma with Multiple Lymphomatous Polyposis Presenting With Intussusceptions
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. The gastrointestinal tract is the predominant site of extranodal involvement in the form of multiple lymphomatous polyposis. Multiple lymphomatous polyposis due to mantle cell lymphoma presenting with intussusception is ...
متن کاملEstablishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma.
BACKGROUND AND OBJECTIVES Mantle cell lymphoma (MCL) cell lines are difficult to generate; only nine lines have been described so far and few of them have been thoroughly characterized. DESIGN AND METHODS We established MAVER-1, a new MCL cell line, obtained from a leukemic MCL harboring both a t(11;14) translocation and a MYC rearrangement, and used immunohistochemistry, flow cytometry, mole...
متن کاملMantle Cell Lymphoma
American Society of Hematology in the first 2 years has also been reduced by 50% in the rituximab-containing treatment arm. These preliminary findings in a pilot study echo the results of previously published studies in advanced disease and provide a lead for future comparative trials. Although the majority of patients with limited disease can be cured using a brief course of doxorubicincontain...
متن کاملMantle Cell Lymphoma.
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2012
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2012.370